TC BioPharm LtdNASDAQ:TCBPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3950
- TODAY'S CHANGE (%)0.0271 (7.3661%)
- Bid / Lots0.3810/ 10
- Ask / Lots0.3998/ 39
- Open / Previous Close0.3952 / 0.3679
- Day Range
- 52 Week Range
- Volume560,456
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TCBP |
|---|---|---|
| 09:32 ET | 16991 | 0.399799 |
| 09:33 ET | 11588 | 0.3701 |
| 09:35 ET | 1760 | 0.3837 |
| 09:37 ET | 2190 | 0.3781 |
| 09:39 ET | 4298 | 0.3837 |
| 09:42 ET | 7670 | 0.386849 |
| 09:44 ET | 6180 | 0.389899 |
| 09:46 ET | 3398 | 0.3864 |
| 09:48 ET | 1100 | 0.3897 |
| 09:50 ET | 450 | 0.38297 |
| 09:51 ET | 6100 | 0.3789 |
| 09:55 ET | 260 | 0.3801 |
| 09:57 ET | 1800 | 0.3801 |
| 10:00 ET | 135 | 0.38 |
| 10:04 ET | 2301 | 0.386 |
| 10:08 ET | 947 | 0.3789 |
| 10:09 ET | 3166 | 0.37 |
| 10:11 ET | 1300 | 0.3878 |
| 10:15 ET | 500 | 0.38 |
| 10:18 ET | 4000 | 0.3801 |
| 10:20 ET | 1000 | 0.3801 |
| 10:22 ET | 2038 | 0.3801 |
| 10:24 ET | 5993 | 0.3801 |
| 10:27 ET | 7080 | 0.386 |
| 10:29 ET | 350 | 0.3701 |
| 10:31 ET | 4046 | 0.3781 |
| 10:36 ET | 31200 | 0.3712 |
| 10:38 ET | 5428 | 0.38 |
| 10:42 ET | 4400 | 0.3759 |
| 10:44 ET | 2750 | 0.381499 |
| 10:45 ET | 3300 | 0.3759 |
| 10:49 ET | 2000 | 0.3703 |
| 11:09 ET | 4749 | 0.3704 |
| 11:12 ET | 40130 | 0.386 |
| 11:16 ET | 45244 | 0.383 |
| 11:18 ET | 3740 | 0.383 |
| 11:21 ET | 1100 | 0.387799 |
| 11:23 ET | 810 | 0.3839 |
| 11:25 ET | 1000 | 0.384 |
| 11:27 ET | 658 | 0.38395 |
| 11:30 ET | 4652 | 0.384 |
| 11:34 ET | 400 | 0.3844 |
| 11:36 ET | 900 | 0.3859 |
| 11:38 ET | 203 | 0.3855 |
| 11:39 ET | 2900 | 0.3849 |
| 11:43 ET | 5200 | 0.3849 |
| 11:45 ET | 200 | 0.3859 |
| 11:50 ET | 33883 | 0.3844 |
| 11:59 ET | 400 | 0.39 |
| 12:01 ET | 1100 | 0.39 |
| 12:06 ET | 100 | 0.385 |
| 12:14 ET | 10800 | 0.385 |
| 12:15 ET | 2426 | 0.389029 |
| 12:17 ET | 1020 | 0.3855 |
| 12:19 ET | 263 | 0.385 |
| 12:21 ET | 997 | 0.389509 |
| 12:24 ET | 2000 | 0.385001 |
| 12:28 ET | 1273 | 0.3897 |
| 12:33 ET | 316 | 0.3875 |
| 12:35 ET | 33688 | 0.38 |
| 12:37 ET | 1268 | 0.385 |
| 12:39 ET | 2000 | 0.39 |
| 12:48 ET | 7360 | 0.3875 |
| 12:50 ET | 2523 | 0.389 |
| 12:51 ET | 4768 | 0.387 |
| 12:55 ET | 100 | 0.3852 |
| 01:04 ET | 3002 | 0.3997 |
| 01:06 ET | 1000 | 0.399799 |
| 01:08 ET | 660 | 0.399699 |
| 01:09 ET | 2500 | 0.3851 |
| 01:13 ET | 17930 | 0.3918 |
| 01:20 ET | 1800 | 0.3918 |
| 01:22 ET | 360 | 0.3918 |
| 01:24 ET | 100 | 0.394249 |
| 01:26 ET | 1300 | 0.393999 |
| 01:31 ET | 160 | 0.3975 |
| 01:40 ET | 2772 | 0.3901 |
| 01:45 ET | 100 | 0.3901 |
| 01:47 ET | 14433 | 0.3881 |
| 01:56 ET | 994 | 0.3901 |
| 02:00 ET | 283 | 0.39418 |
| 02:07 ET | 300 | 0.3876 |
| 02:09 ET | 6111 | 0.385 |
| 02:16 ET | 100 | 0.385001 |
| 02:30 ET | 500 | 0.3912 |
| 02:32 ET | 100 | 0.39 |
| 02:34 ET | 10000 | 0.3899 |
| 02:41 ET | 1514 | 0.387499 |
| 02:45 ET | 8290 | 0.39 |
| 02:54 ET | 6585 | 0.385 |
| 02:57 ET | 2821 | 0.385 |
| 03:08 ET | 17000 | 0.39 |
| 03:12 ET | 256 | 0.39 |
| 03:15 ET | 300 | 0.3875 |
| 03:19 ET | 6350 | 0.39 |
| 03:32 ET | 4140 | 0.3901 |
| 03:33 ET | 1008 | 0.390201 |
| 03:35 ET | 600 | 0.3973 |
| 03:37 ET | 2758 | 0.3851 |
| 03:39 ET | 7552 | 0.3912 |
| 03:46 ET | 100 | 0.3851 |
| 03:48 ET | 450 | 0.3852 |
| 03:50 ET | 1370 | 0.3885 |
| 03:51 ET | 4248 | 0.394 |
| 03:55 ET | 2785 | 0.395 |
| 03:57 ET | 21167 | 0.3999 |
| 04:00 ET | 1075 | 0.395 |
Nov 27, 2023
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia, from 8:45AM ET on Monday Nov 27, 2023 by Dow Jones
8:45AM ET on Monday Nov 27, 2023 by Dow Jones
Nov 14, 2023
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results, from 10:00AM ET on Tuesday Nov 14, 2023 by Dow Jones
10:00AM ET on Tuesday Nov 14, 2023 by Dow Jones
Nov 2, 2023
DJ TC BioPharm Inks Trial-Management Deal With Fortrea Amid Cost Cutting, from 2:00PM ET on Thursday Nov 02, 2023 by Dow Jones
2:00PM ET on Thursday Nov 02, 2023 by Dow JonesTC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials, from 1:30PM ET on Thursday Nov 02, 2023 by Dow Jones
1:30PM ET on Thursday Nov 02, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TC BioPharm Ltd | 3.4M | 0.0x | --- |
Petros Pharmaceuticals Inc | 3.5M | -0.2x | --- |
Stemcell Holdings Inc | 1.6M | 750.0x | --- |
Pulmatrix Inc | 7.5M | -0.5x | --- |
Fresh Tracks Therapeutics Inc | 5.0M | -0.3x | --- |
Qualigen Therapeutics Inc | 3.7M | -0.2x | --- |
Company Information
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
Contact Information
- Headquarters
- Maxim 1, 2 Parklands WayHONITON, United Kingdom ML1 4WR
- Phone
- 141-433-7557
- Fax
- ---
Executives
- Chief Executive Officer
- Michael Leek
- Chief Financial Officer
- Martin Thorp
- Chief Operating Officer
- Angela Scott
- Company Secretary
- Toby Rintoul
- Director
- Bryan Kobel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4M |
|---|---|
Revenue (TTM) | $3.6M |
Shares Outstanding | 936.4K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-17.33 |
Book Value | $-0.13 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 1.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.57% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
